Mavrilimumab improves outcomes in COVID-19 pneumonia with hyperinflammation
03 Aug 2020
byAudrey Abella
Adding the anti-GM-CSF* receptor-α monoclonal antibody mavrilimumab to standard care (SC) improved clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia and systemic hyperinflammation who were not under mechanical ventilation (MV), an Italian study has shown.
